A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Public ClinicalTrials.gov record NCT00661609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer
Study identification
- NCT ID
- NCT00661609
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2008 (Type not available)
- Primary completion
- May 2009 (Actual)
- Completion
- Dec 2009 (Actual)
- Last update posted
- Jan 12, 2011
2008 – 2009
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Palo Alto | California | — | — |
| Research Site | San Bernardino | California | — | — |
| Research Site | Southington | Connecticut | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Marietta | Georgia | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Scarborough | Maine | — | — |
| Research Site | Ann Arbor | Michigan | — | — |
| Research Site | Minneapolis | Minnesota | — | — |
| Research Site | Hackensack | New Jersey | — | — |
| Research Site | Morristown | New Jersey | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Woonsocket | Rhode Island | — | — |
| Research Site | Seattle | Washington | — | — |
| Research Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00661609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2011 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00661609 live on ClinicalTrials.gov.